Table 3.
Preclinical studies related to combination therapy of Gemcitabine with recombinant or native oncolytic viruses.
| Sr. No | Viurses | Alterations in viruses | Other therapies | Study outcomes | reference |
|---|---|---|---|---|---|
| 1 | YDC002 Adenovirus |
+ relaxin | – | Low (0.01-0.05µ M) dose shows effective results |
jung2017oncolytic |
| 2 | Ad5-3Δ -A20T Adenovirus |
– | – | high selectivity to cancer cells | (144) |
| 3 | shRNA-encoding adenovirus |
– | TRAIL | tumor size regression | (149) |
| 4 | Myb34.5 herpes simplex virus |
– | Low dose shows effective tumor size reduction |
gayral2015targeted | |
| 5 | oVV-Smac vaccinia virus |
+ Smac gene | – | Increases apoptosis and cytotoxic effect of Gemcitabine |
chen2019gemcitabine |
| 6 | VV-ING4 vaccinia virus |
+ inhibitor of ING4 gene | – | Helps Gemcitabine to work more effectively as anticancer therapy |
wu2017ing4 |
| 7 | GLV-168 vaccinia virus |
β -galactosidase, β -glucuronidase, and Ruc-GFP |
Nab-paclitaxel | – | (195) |
| 8 | H-1PV Parvovirus | – | – | significant reduction of tumor size | (206) (207) |
| 9 | MeV Measles virus | – | – | > 50% reduction of tumor size | (215) |
| 10 | VSV- Δ M51-GFP Vesicular Stomatitis Virus |
– | – | (230) |